首页 正文

Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer

{{output}}
Until recently, the treatment of patients with advanced non-small-cell lung cancer (NSCLC) whose tumors did not have a targetable genetic alteration was cytotoxic chemotherapy alone. This treatment provided only modest survival benefit. The introduction of imm... ...